A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

NCT05022849 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: JNJ-75229414
DRUG: Bridging Therapy

Sponsor

Janssen Research & Development, LLC